Refine by
Immune Antibody Articles & Analysis: Older
16 news found
As a global leading supplier of raw materials, antibodies, and reagents for bio-technology industry, Creative Diagnostics recently launches a series of NiV recombinant antigen and antibody pairs. ...
The GlyMab™ technology is part of Scancell’s antibody portfolio, joining AvidiMab® , a technology that can be applied to all antibodies (regardless of the technology used to generate them), enhancing their potency and ability to directly kill tumour cells. ...
ByScancell
The Phase 1 trial is testing Scancell’s two clinical candidates, SCOV1 and SCOV2 (COVIDITY), which in preclinical models have induced high titre antibodies and potent T cells against both the S and N antigens, including responses that cross-react with the Delta and Omicron variants. ...
ByScancell
“Omicron exposes limitations of antiviral monoclonal antibody therapy in COVID-19 – a clear opportunity for host-cell directed drugs like zapnometinib. ...
PHILADELPHIA, March 08, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, today announced that five abstracts have been selected for poster or symposium presentations at the American Association for ...
As reported in several recent high-profile publications, Nature Biotechnology and Nature Immunology, the SNAPvaxTM platform uses self-assembly to co-deliver multiple antigens and immunomodulators in nanoparticles of precise, programmable size and composition, thereby enabling immunotherapy product candidates with tighter control over immune responses. The SNAPvaxTM platform can ...
Immune Biosolutions is pleased to announce the start of Phase I clinical trial for its immunotherapy (IBIO123) treatment, whose antibodies have the potential to neutralize and eliminate COVID-19 and its variants. ...
These tests include Nucleic Acid Tests (NATs), antigen/antibody tests, and antibody tests. Nucleic Acid Test (NATs) NATs test for actual virus present in the blood. ...
ByFluxergy
Featured products: Cytokine-expressing Oncolytic Herpes Simplex Virus 1 (ΔΔICP0), CMV-IL-15 Cytokine-expressing Oncolytic Vaccinia Virus Western Reserve (ΔE3L), pSE/L-mLIGHT Cytokine-expressing Oncolytic Herpes Simplex Virus 1 (ΔICP27), CMV-CCL17 Besides, the product portfolio also ranges from immune checkpoint antibody-armed OVs, ...
Fibroblast Activating Protein(FAP) is selectively upregulated on the cancer associated fibroblasts (CAF) that play an important role in the immune suppressive tumor microenvironment found in many stromally dense tumors that are refractory to checkpoint inhibitors. ...
Immune Biosolutions, an innovative biotechnology company, receives $13.44M from the Government of Canada’s Strategic Innovation Fund (SIF) to develop its promising immunotherapy whose antibodies have the potential to neutralize and eliminate COVID-19 and its variants. ...
DNA medicines are composed of optimized DNA plasmids, which are small circles of double-stranded DNA that are synthesized or reorganized by a computer sequencing technology and designed to produce a specific immune response in the body. INOVIO's DNA medicines deliver optimized plasmids directly into cells intramuscularly or intradermally using INOVIO's proprietary hand-held ...
Antibody tests Antibody tests determine whether an individual has been infected with the virus and has developed an immune response (antibodies) against the virus. Antibody tests use a blood sample and can be processed relatively quickly, yet they will not identify people with an early infection, nor can they ...
ByMiraDx
“IBio’s Nebula platform provides a new angle to antibody discovery with four families of technologies integrated within a single platform to deliver innovative antibody therapies in key disease areas. ...
Funding will support the demonstration of the in vivo efficacy and safety of novel therapeutic chicken antibodies generated by Immune Biosolutions’ proprietary Nebula™ Platform. ...
In addition to providing additional space, the new facility will grant access to state-of-the-art equipment to follow the increasing demand for Immune Biosolutions’ Nebula Antibody Platform, and will allow additional R&D initiatives in the development of new life- saving technologies. This marks an important milestone for Immune ...